a.ostergaard98/100
Storage condition for the stability statement stated on the certificate.
SGN — Sangon Biotech (Shanghai) Co., Ltd.
Shanghai, CN · established 2004. The index holds 221 assay reports across 37 batches and 21 compounds, contributed by 6 laboratories. Every figure below is computed from those records and from nothing else.
Where SGN sells
Sangon Biotech (Shanghai) Co., Ltd. sells from its own storefront. The link is marked nofollow and sponsored: it exists so the figures on this scorecard can be read against what the supplier itself publishes. The index is paid nothing for it and a link is not an assessment.
Every figure above describes lots the index has seen. It says nothing about the lot you are offered, and the only check that does is the one on the certificate against the vial.
Block 1
Identification
Business facts, held constant across the index and not derived from the data. The index sells nothing and takes no supplier payment for placement; the storefront link below is marked nofollow and sponsored so a record can be checked against the seller, and is not a recommendation.
- Legal name
- Sangon Biotech (Shanghai) Co., Ltd.
- Short code in this index
- SGN
- Also known as
- SGN · SGN Biotech · Sangon Biotech (Shanghai)
- Domain
- sangonbio.com →
- City
- Shanghai
- Region
- Shanghai
- Country
- CN
- Established
- 2004
- First record in index
- 28 Jan 2024
- Most recent record
- 14 Sep 2026
Block 1b
Dispatch and regional stock
Counted from the chain-of-custody line on this supplier's own records, which names the route each vial travelled to the laboratory, and from the on-record reviews below. The index has no sight of any supplier's warehouse network and publishes none.
Domestic-warehouse route
14.9%
n=221
Retail, shipped to the buyer
69.2%
n=221
Direct to the laboratory
13.1%
n=221
Median courier leg, direct despatch
7d
n=29
| Route to the laboratory | Records | Share |
|---|---|---|
| Domestic warehouse despatch | 33 | 14.9% |
| Retail purchase, shipped to the buyer | 118 | 53.4% |
| Retail purchase via a third-party forwarder | 35 | 15.8% |
| Supplier despatch direct to the laboratory | 29 | 13.1% |
| Laboratory retained-sample archive | 6 | 2.7% |
Every record here carries a chain-of-custody line and that line names the route the vial travelled. Of the 221 SGN records the index holds, 33 reached the contributing laboratory from a domestic warehouse rather than as a cross-border consignment, covering 15 of the 21 compounds SGN is represented by here — Tirzepatide, Afamelanotide, GHRP-6, TB-500, N-Acetyl Semax Amide, ARA-290 and 9 further compounds. Those are the SGN lines this index has actually seen arrive from regional stock, and they are a count of consignments rather than a stock listing: a line missing from them may simply never have been submitted for assay.
One contributor on the record below documents SGN stock held in Poland, with a transit of 2 working days against a quoted 2. Poland is the only regional stock location named anywhere in SGN's record here, and one consignment described by one buyer is exactly that. It is not a warehouse list and the index has not verified it.
The index measures nothing about lead time — it assays material, it does not buy it. What it has is SGN's own reviewers: 3 of the 26 on-record reviews state a quoted window and what happened against it, and 1 of them describes same-day dispatch. Where SGN despatched a sample direct to a laboratory, the courier leg ran a median 7 days across 29 such consignments — that is a transit time the index can see, and it is not the same thing as a lead time. The reviews are reproduced in full in Block 11.
Block 2
Headline statistics
Each figure carries the n it was computed from. The n= badge next to a statistic is the number of records it was computed from. Below n=8 the badge is amber. Below n=3 the statistic is suppressed and the individual values are shown instead.
Median purity
98.58%
n=221
Interquartile range
0.86pp
n=221
10th percentile
97.84%
n=221
Pass rate vs index spec
88.2%
n=221
Median recovery vs claim
97.0%
n=124
Median water
4.83%
n=221
Median |mass error|
2.7ppm
n=188
Records carrying a flag
32.1%
n=221
Block 3
Reproducibility across independent tests of one lot
Where the same physical lot was assayed more than once, the spread between those results is a property of the material and the fill, not of the market. It is the rarest and most informative statistic on this page, and it exists only for lots someone tested twice.
Median within-batch spread
0.81pp
n=27
Index median spread
0.67pp
n=28
Lots tested 3+ times
27
n=37
Across the 27 SGN lots in the index with three or more independent assays, the median spread between the highest and lowest purity result on one lot is 0.81 pp. Interpreting that number requires the laboratory repeatability figures: the best contributing laboratory here repeats to 0.16 pp and the worst to 0.34 pp, so a within-lot spread under about 0.5 pp is indistinguishable from measurement noise and a spread above 1 pp is a statement about the material.
Block 4
Supplier certificate against independent measurement
The supplier's own COA purity figure for a lot, minus the median of the index's independent observations of the same physical lot. Positive means the certificate reads higher than the measurement. Rule AX-R05 fires above 1.5 pp.
Median COA divergence
+0.18pp
n=37
Index median divergence
+0.06pp
n=28
Divergences in the supplier's favour
73%
n=37
Divergences beyond 1 pp
3%
n=37
Block 5
Provenance — where the tested material came from
Supplier-supplied samples are weaker evidence than independently purchased ones, because the supplier chose the vial. The index measures the size of that effect rather than assuming it.
Buyer-sourced median
98.50%
n=186
Supplier-supplied median
99.06%
n=29
Supplier-supplied share of records
13.1%
n=221
Block 6
Documentation completeness
The score is not an opinion about paperwork. Each component is the share of SGN batches in the index whose certificate carries that field, weighted as set out on the scoring rubric.
Documentation score
72/100
n=37
Index median score
85/100
n=28
| Certificate field | Batches carrying it | Rubric weight | |
|---|---|---|---|
| Purity figure stated | 100% | 25 points | |
| Analytical method stated (column, gradient, wavelength) | 54% | 25 points | |
| Peptide content stated | 49% | 20 points | |
| Endotoxin stated | 32% | 15 points | |
| Named impurities rather than a total | 29% | 15 points |
Block 7
Coverage by compound
The delta column is this supplier's median minus the index-wide median for the same compound, which is the only comparison worth making: comparing a supplier's aggregate against another supplier's aggregate compares their product mixes as much as their process control.
| Compound | Class | Reports | Median % | Index median % | Δ (pp) | Index spec | Pass % |
|---|---|---|---|---|---|---|---|
| Tirzepatide | Incretin | 60 | 98.19 | 98.55 | -0.36 | 97.0 | 98 |
| Semaglutide | Incretin | 18 | 98.39 | 98.89 | -0.50 | 97.0 | 100 |
| TB-500 | Tissue-repair | 17 | 99.16 | 99.53 | -0.37 | 98.5 | 94 |
| GHRP-6 | Growth-hormone | 16 | 99.17 | 99.54 | -0.37 | 99.0 | 63 |
| N-Acetyl Semax Amide | Neuroactive | 13 | 98.61 | 99.35 | -0.74 | 98.5 | 62 |
| ARA-290 | Tissue-repair | 12 | 98.31 | 99.42 | -1.11 | 98.0 | 92 |
| GHK-Cu | Tissue-repair | 12 | 98.22 | 98.56 | -0.34 | 97.0 | 100 |
| Afamelanotide | Melanocortin-receptor | 11 | 98.42 | 99.06 | -0.64 | 98.0 | 100 |
| Triptorelin | Hypothalamic | 10 | 98.80 | 99.41 | -0.60 | 98.5 | 80 |
| BPC-157 | Tissue-repair | 9 | 98.59 | 99.16 | -0.57 | 98.0 | 100 |
| Sermorelin | Growth-hormone | 7 n=7 | 99.16 | 99.06 | +0.10 | 98.0 | 100 |
| Selank | Neuroactive | 7 n=7 | 98.28 | 99.59 | -1.31 | 99.0 | 0 |
| SLU-PP-332 | Non-peptide | 6 n=6 | 98.42 | 98.88 | -0.46 | 98.0 | 100 |
| Thymosin α1 | Tissue-repair | 6 n=6 | 99.50 | 99.40 | +0.10 | 97.5 | 100 |
| CJC-1295 (no DAC) | Growth-hormone | 5 n=5 | 99.36 | 99.09 | +0.27 | 98.0 | 100 |
| MGF | Growth-hormone | 3 n=3 | 99.39 | 99.29 | +0.10 | 97.5 | 100 |
| IGF-1 LR3 | Growth-hormone | 3 n=3 | 98.26 | 98.28 | -0.02 | 95.0 | 100 |
| PT-141 (Bremelanotide) | Melanocortin-receptor | 2 n=2 | n<3 | 99.38 | — | 98.5 | 50 |
| Ipamorelin | Growth-hormone | 2 n=2 | n<3 | 99.47 | — | 99.0 | 0 |
| L-Glutathione (reduced) | Short | 1 n=1 | n<3 | 99.33 | — | 98.5 | 100 |
| Liraglutide | Incretin | 1 n=1 | n<3 | 99.00 | — | 97.5 | 100 |
Full per-compound breakdown with distributions and caveats →
Block 8
Quarterly trend
Submission volume is not market share and a quarterly median is not a trend unless the compound mix held still. Both caveats apply to every row below.
Median purity by quarter
Quarters with fewer than two purity records are gaps in the line rather than zeroes.
Coverage growth
Records added per quarter. Growth here is index coverage, not supplier volume.
| Quarter | Batches | Reports | Median purity | Range | Flagged |
|---|---|---|---|---|---|
| 2024-Q1 | 1 | 6 | 99.20 | 98.91–99.42 | 1 |
| 2024-Q2 | 1 | 15 | 98.16 | 97.83–99.72 | 5 |
| 2024-Q3 | 1 | 12 | 98.56 | 98.30–99.36 | 12 |
| 2024-Q4 | 6 | 29 | 98.91 | 97.86–99.93 | 6 |
| 2025-Q1 | 5 | 21 | 98.28 | 97.83–99.54 | 4 |
| 2025-Q2 | 6 | 28 | 98.77 | 97.14–99.53 | 9 |
| 2025-Q3 | 9 | 57 | 98.74 | 96.49–99.92 | 23 |
| 2025-Q4 | 2 | 13 | 98.44 | 98.01–99.34 | 3 |
| 2026-Q1 | 1 | 7 | 98.89 | 98.52–99.82 | 4 |
| 2026-Q2 | 4 | 31 | 98.32 | 97.76–99.42 | 3 |
| 2026-Q3 | 1 | 2 | n<3 | 98.76–99.93 | 1 |
Block 9
Which laboratory produced these numbers
Laboratories disagree with each other by a measured amount. A supplier tested mostly by one laboratory carries that laboratory's offset in its aggregate, and the adjusted column removes it.
| Laboratory | Reports | Median purity | Lab bias (pp) | Bias-adjusted |
|---|---|---|---|---|
| Janoshik | 87 | 98.68 | +0.00 | 98.68 |
| PeptideMeter | 43 | 98.46 | -0.05 | 98.51 |
| Medutest | 33 | 98.63 | +0.08 | 98.55 |
| VendorInvestigate | 20 | 98.28 | -0.11 | 98.39 |
| Nordanalyt | 18 | 98.85 | +0.02 | 98.83 |
| Kestrel | 20 | 98.84 | +0.24 | 98.61 |
Bias figures are estimated from paired same-lot comparisons and are published with their confidence intervals on inter-lab agreement.
Block 10
What this data does and does not show
Block 11
On-the-record reviews 26
Reviews are signed statements from index contributors about their own testing of this supplier's material. They are opinions attached to evidence, and they are not used in any statistic on this page.
90.0/ 100573 ratings across the index network
er.adeyemi97/100
Purity by RP-HPLC, wavelength stated, stability-indicating method named. Determination is reproducible from the certificate alone. Vial-to-vial mass variation under 2%.
l.lokken96/100
Single lot identifier across the whole consignment. Intra-consignment comparison valid. Nothing unsecured in the consignment.
m.beaulieu95/100
Packing: a rigid outer with no rattle anywhere in it.
m.salgado99/100
Reconstitution of AOD-9604 5 mg: clear on contact, no haze, no particulate. Technical response inside four hours, working day.
c.halonen98/100
Blind submission of survodutide 10 mg to VendorInvestigate, origin withheld. 97.4% against 97.1% declared. Record covers the lots named. Not generalised.
n.malinowski97/100
Fill uniformity: 11 units weighed against declared fill, all within 2%. Documentation practice, not a single purity figure, is the substance here.
f.lokken96/100
10 orders, 12 months. No substitution, no reformulation, no post-payment unavailability. Subsequent orders placed with the same supplier.
h.zamora96/100
Water content by Karl Fischer, method named. Not medical advice.
da.nilsen95/100
Direct-supply material 97.2%. Intermediary vial, same nominal description, 97.0%. Further submissions on later lots would improve coverage.
na.laurent100/100
Vials inspected individually on receipt, all sound. Technical response inside four hours, working day. Independent verification of individual lots still required.
h.wikstrom96/100
Transit 2 days from stock held in Poland against a quoted 2. Customs documentation correct at first presentation. Contributor declares no interest beyond the transaction.
p.kjaer97/100
Repeat determination at 15 months: 98.9%. Original: 98.9%. No drift detected in this sample.
r.malinowski98/100
Orthogonal identity present: mass spectrometry alongside the chromatographic determination. Vial-to-vial mass variation under 2%.
i.asante100/100
Water content on the first certificate with the method named. Material returned 97.1%. No further comment.
p.hovland97/100
Lot SGN-25-899 submitted to PeptideMeter. Declared 98.7%, reported 98.6%. Delta inside method repeatability. No excipient. Cake intact. Research use. Not approved for human administration.
h.batista98/100
Published stock status matched availability. Same-day dispatch. Submitted to the index in full.
as.novak99/100
Release signed and dated, named individual. n=1, declared as n=1.
r.lindholm98/100
Peptide content reported separately from chromatographic purity across all 10 certificates held. Signature and release date present.
an.lindqvist99/100
Cross-check: PeptideMeter and Medutest, same lot, agreement to 0.1 points. Both agree with the declared figure.
ah.novak99/100
Certificate carries the residual-solvent screen. Complete against the index minimum data set at first issue.
ma.vukovic98/100
Supplementary certificate for a lot released 9 months earlier retrieved from supplier records on request. Subsequent orders placed with the same supplier.
e.salinas100/100
Five orders, tracking live from despatch on each and no carrier gap on any. Technical response inside four hours, working day.
ha.beaulieu95/100
Custom synthesis delivered 4 days inside the quoted schedule at the specified purity. Declared and independent figures differ by less than repeatability. Figures as reported by the named service. Not reproduced by the index.
n.demir100/100
Quote correct at first issue and the price held to invoice. Documentation complete at first issue. Independent verification of individual lots still required.
m.lokken97/100
Residual-solvent screen included unrequested. Vial-to-vial mass variation under 2%.
Block 12
Most recent records
Block 13
Contributor annotations on SGN records 372
Annotations are this index's only discussion surface: signed technical comments attached to a specific record by a named contributor. They are not moderated for agreement with the index's own arithmetic. The most recent on SGN material are below, each linked to the record it sits on.
On compounds with a single supplier, independently purchased records are the only thing preventing the evidence base from being entirely supplier-generated. They matter disproportionately there.
The index grades identity by instrument class, not by the ppm figure alone: "confirmed" where the determination was made at high resolution, "consistent with" where it was not. The status block above says which applies to this record, and it is worth reading before the number.
The gradient is on this record, which is the only reason any of this can be said. Most certificates in this market do not state one at all.
Epimerisation during activation produces a diastereomer that is mass-identical and only chromatographically separable. At this gradient length the separation exists, and 99.93 % is net of it.
Two retail purchases of the same lot from different buyers are genuinely independent. Two aliquots of one purchase are not, and the index does not treat them as such.
Where a supplier-supplied result on the same lot also exists, the pair is the informative object rather than either record alone. The batch page shows whether one does.
Two instruments or it is not confirmed, and this record is one instrument. It is a good one instrument, and the index records it as confirmed rather than corroborated for that reason.
Percent by weight of the cake throughout, stated once and applied consistently. Mixing bases across the four slots is the commonest way a balance fails to close.
Every annotation the index holds on SGN material sits on its own record; the full set is reachable from the record listing and from each contributor's page. To read them against what SGN itself publishes, open sangonbio.com → alongside.
Block 14
Where to buy SGN
Sangon Biotech (Shanghai) Co., Ltd. sells direct from sangonbio.com. Everything on this page describes lots the index has already seen; the certificate that matters is the one that arrives with the vial you order, and the lot code on it should match the vial. Ask for the lot-specific document rather than the batch-level summary, and ask for the integration report if you intend to reconcile the figure yourself.
Go to the SGN store at sangonbio.com →
Marked nofollow and sponsored. The index is paid nothing for it, takes no commission, and a link is not an assessment. Research compounds. Not medical advice. Nothing on this site is a safety assessment and nothing on it is approved for human use.